The discovery and development of gefapixant
Author:
Funder
Roche
Publisher
Elsevier BV
Subject
Cellular and Molecular Neuroscience,Clinical Neurology,Endocrine and Autonomic Systems
Reference77 articles.
1. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study;Abdulqawi;Lancet,2015
2. Effects of aerosolized adenosine 5’-triphosphate vs adenosine 5’-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma;Basoglu;Chest,2005
3. Peristalsis is impaired in the small intestine of mice lacking the P2X3 subunit;Bian;J. Physiol.,2003
4. Pharmacological characterization of recombinant human and rat P2X receptor subtypes;Bianchi;Eur. J. Pharmacol.,1999
5. A P2X purinoceptor cDNA conferring a novel pharmacological profile;Bo;FEBS Lett.,1995
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The discovery and development of gefapixant as a novel antitussive therapy;Expert Opinion on Drug Discovery;2024-08-13
2. Purinergic P2X Receptors as Therapeutic Targets;Ion Channels as Targets in Drug Discovery;2024
3. TO MARKET, TO MARKET–2022: SMALL MOLECULES;Medicinal Chemistry Reviews;2023-11-16
4. Chronic cough relief by allosteric modulation of P2X3 without taste disturbance;Nature Communications;2023-09-20
5. Gefapixant, a Novel P2X3 Antagonist, Protects against Post Myocardial Infarction Cardiac Dysfunction and Remodeling Via Suppressing NLRP3 Inflammasome;Current Medical Science;2023-01-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3